NinePoint Medical Announces U.S. Commercial Availability of the NvisionVLE™ Imaging System

Before you go, we thought you'd like these...
Before you go close icon

NinePoint Medical Announces U.S. Commercial Availability of the NvisionVLEImaging System

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- NinePoint Medical, Inc., an emerging leader in the development of medical devices for advanced optical imaging, today announced the commercial launch of its proprietary NvisionVLE Imaging System in the United States. In addition, NinePoint today announced the launch of its newly redesigned website, www.ninepointmedical.com.

In December 2011, the NvisionVLE Imaging System received 510(k) clearance from the U.S. Food and Drug Administration for use as an imaging tool in the evaluation of human tissue microstructure by providing two-dimensional, cross sectional, real-time depth visualization. Last month, NinePoint received 510(k) clearance to expand the System's indication to include imaging of esophageal tissue microstructure.


Originally developed at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH), NinePoint licensed the imaging technology from MGH in 2010 as part of the largest intellectual property agreement for medical device technology in the hospital's history. The NvisionVLE Imaging System enables physicians and pathologists to endoscopically view real-time, high-resolution, cross sectional images of organs and tissues up to 3mm deep at better than 10 micron resolution.

"For NinePoint, the launch of our NvisionVLE Imaging System is the culmination of many major milestones over the past few years, and a great testament to the hard work of our team," said Charles Carignan, M.D., president and chief executive officer of NinePoint Medical. "It is always a great feeling to release a new medical device and make it available for improving patient care. As the only volumetric, optical coherence tomography (OCT) device for endoscopic and esophageal tissue imaging commercially available in the U.S., the introduction of the NvisionVLE Imaging System represents a significant addition to the current imaging landscape. We are pleased to offer clinicians across the country a new approach to evaluate esophageal tissue microstructure with faster imaging speed and improved image resolution, potentially leading to better biopsy targeting, reduced costs and improved patient outcomes."

About NinePoint Medical, Inc.

NinePoint Medical is positioned to improve patient care through the development of medical devices that enable high resolution in-vivo imaging. The Company was founded on the ideal of convergence, of developing products that could bring together access, diagnosis and treatment. Founded in 2009 with an initial Series A of $33 million, the Company licensed the fundamental optical coherence tomography (OCT) technology from Massachusetts General Hospital (MGH) in 2010 and received its first 510(k) clearance from the U.S. Food and Drug Administration in December 2011. NinePoint launched its lead product, the NvisionVLE™ Imaging System, in the U.S. in May 2013. Backed by Third Rock Ventures and Prospect Venture Partners, NinePoint is headquartered in Cambridge, Mass. For more information, please visit www.ninepointmedical.com.



Pure Communications, Inc.
Susan Heins, 864-286-9597

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:

The article NinePoint Medical Announces U.S. Commercial Availability of the NvisionVLE™ Imaging System originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners